Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design

Alfredo Berruti, Raffaella Bitossi, Gabriella Gorzegno, Alberto Bottini, Palmiro Alquati, Andrea De Matteis, Francesco Nuzzo, Giorgio Giardina, Saverio Danese, Mario De Lena, Vito Lorusso, Antonio Farris, Maria Giuseppa Sarobba, Enza DeFabiani, Giorgio Bonazzi, Federico Castiglione, Cesare Bumma, Gregorio Moro, Paolo Bruzzi, Luiqi Dogliotti

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design'. Together they form a unique fingerprint.

Medicine & Life Sciences